Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022:57:51-77.
doi: 10.1007/7854_2022_331.

The Benefits and Limitations of Stimulants in Treating ADHD

David Coghill  1   2
Affiliations
Review

The Benefits and Limitations of Stimulants in Treating ADHD

David Coghill. Curr Top Behav Neurosci. 2022.

Abstract

This chapter focusses on the benefits and limitations of stimulant medications in the treatment of ADHD. We highlight the key similarities and differences between the different stimulants used to treat ADHD and briefly discuss mechanisms of action, pharmacokinetics, and pharmacodynamics. We will discuss some of the political, ethical, and moral discussions about the use of stimulants including a consideration of the treatment of subsyndromal ADHD and the use of stimulants as cognitive enhancers. We review the comparative efficacy and effectiveness between stimulants and non-pharmacological treatments for ADHD, between stimulant classes and formulations and between stimulant and non-stimulant medications. We discuss the effects on core symptoms, common associated symptoms, cognition, and more distal outcomes including quality of life and functioning and issues related to tolerance, tolerability and adverse effects. Looking at the clinical implications of these findings, we discuss the importance of measurement-based care in the treatment of ADHD. Finally, we will look at the benefits and limitations of stimulants across several different populations and clinical subgroups.

Keywords: ADHD; Amphetamines; Lisdexamfetamine; Methylphenidate; Stimulants.

PubMed Disclaimer

References

    1. Abikoff HB, Vitiello B, Riddle MA, Cunningham C, Greenhill LL et al (2007) Methylphenidate effects on functional outcomes in the preschoolers with attention-deficit/hyperactivity disorder treatment study (PATS). J Child Adolesc Psychopharmacol 17(5):581–592. https://doi.org/10.1089/cap.2007.0068 - DOI - PubMed
    1. Academy of Medical Sciences (2008) In: Sciences AOM (ed) Brain science, addiction and drugs. Academy of Medical Sciences, London
    1. Adamo N, Seth S, Coghill D (2015) Pharmacological treatment of attention-deficit/hyperactivity disorder: assessing outcomes. Expert Rev Clin Pharmacol 8(4):383–397. https://doi.org/10.1586/17512433.2015.1050379 - DOI - PubMed
    1. American Academy of Pediatrics (2000) Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics 105(5):1158–1170. https://doi.org/10.1542/peds.105.5.1158 - DOI
    1. Banaschewski T, Bauer M, Bea M, Dopfner M, Gelb M, Grosse KP (2017) Langfassung der interdisziplinären evidenz- und konsensbasierten (S3) Leitlinie “Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) im Kindes-, Jugend- und Erwachsenenalter” [Online]. https://www.awmf.org/leitlinien/detail/ll/028-045.html . Accessed 15 Oct 2019

MeSH terms

Substances

LinkOut - more resources